A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
Authors:
- Z. Z. N. YiuZYZ. Z. N. Yiu
- K. J. MasonKMK. J. Mason
- C. H. SmithCSC. H. Smith
- on behalf of the BADBIR Study GroupOGon behalf of the BADBIR Study Group
Open Access
- 1 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (6) , 1265-1271
Abstract
Background Patients recruited in randomised controlled trials (RCT) for biologic therapies in psoriasis are not fully representative of the real‐world psoriasis population. Objectives To investigate whether patient characteristics are associated with being a RCT psoriasis; to estimate the difference in the incidence of severe adverse events (SAEs) and the response rate between RCT and real‐world populations of patients on biologic therapies for psoriasis using a standardisation method. Methods Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR) were appended to individual participant‐level data from two RCTs assessing ustekinumab in psoriasis patients. Baseline variables were assessed for association of being in a RCT using a multivariable logistic regression model. Propensity score weights were derived to reweigh the registry population so that variables had the distribution in the trial population. We measured the C‐statistic of the model with trial status as the dependent variable; and the risk difference in the incidence rate of serious adverse events (SAE) in the first year and Psoriasis Area and Severity Index (PASI) after 6 months in the BADBIR cohort before and after weighting. Results 6790 registry and 2021 RCT participants were included. The multivariable logistic regression model had a C‐statistic of 0.82 (95% C.I. 0.81, 0.83). The risk difference for incidence rate of SAE and proportion of patients with PASI below 1.5 were 9.27 (95%CI ‐3.91,22.50) per 1000 person‐years and 0.95 (‐1.98,4.15) respectively. Conclusions Our results suggest that RCTs of biologic therapies in psoriasis patients are not fully representative of the real‐world population, but this lack of external validity does not account for the efficacy‐effectiveness gap.Keywords
Funding Information
- Research Trainees Coordinating Centre (DRF‐2015‐08‐089)
This publication has 14 references indexed in Scilit:
- Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRJAMA Dermatology, 2018
- Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registriesRheumatology, 2017
- Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target PopulationAmerican Journal of Epidemiology, 2017
- Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-AnalysisJournal of Investigative Dermatology, 2017
- Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug developmentBritish Journal of Dermatology, 2016
- A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial resultsTrials, 2015
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Journal of Investigative Dermatology, 2015
- Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic TherapyArchives of Dermatology, 2012
- The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectivesBritish Journal of Dermatology, 2012
- Generalizing Evidence From Randomized Clinical Trials to Target Populations: The ACTG 320 TrialAmerican Journal of Epidemiology, 2010